ThermoGenesis Holdings, Inc. (THMO)
|52 Week Range||1.03-22.95|
|1y Target Est||-|
|DCF Unlevered||THMO DCF ->|
|DCF Levered||THMO LDCF ->|
|Debt / Equity||-|
Upgrades & Downgrades
Latest THMO news
ThermoGenesis Holdings, Inc. (THMO) Q1 2023 Earnings Call Transcript
15 May 2023
ThermoGenesis Holdings, Inc. (NASDAQ:THMO ) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Paula Schwartz - Rx Communications Chris Xu - Chief Executive Officer Jeff Cau...
Why Is ThermoGenesis (THMO) Stock Up 54% Today?
16 March 2023
ThermoGenesis (NASDAQ: THMO ) stock is rocketing higher on Thursday after the company announced new cGMP Suites. These cGMP Suites are for early-stage life science and cell gene therapy companies.
Why ThermoGenesis Stock Is Soaring Wednesday
15 March 2023
ThermoGenesis said it plans to rent out its current Good Manufacturing Practices suites in the second and third quarters. The company was nearly delisted from the Nasdaq last year.
THMO Stock Alert: Why ThermoGenesis Is Up 95% Today
15 March 2023
What's causing ThermoGenesis Holdings (NASDAQ: THMO ) stock traders to suddenly go on a buying binge? Evidently, the share-price rally is prompted by ThermoGenesis's announcement that it's launching a...
ThermoGenesis Holdings, Inc. (THMO) CEO Dr. Chris Xu on Q3 2022 Results - Earnings Call Transcript
12 November 2022
ThermoGenesis Holdings, Inc. (NASDAQ:THMO ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Paula Schwartz - Rx Communications Dr. Chris Xu - Chief Executive Officer...
ThermoGenesis Holdings, Inc. (THMO) Reports Q3 Loss, Misses Revenue Estimates
10 November 2022
ThermoGenesis Holdings, Inc. (THMO) delivered earnings and revenue surprises of -233.33% and 28.79%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead fo...
ThermoGenesis Holdings to Announce Financial Results for the Third Quarter Ended September 30, 2022 ...
7 November 2022
Conference Call to be Held on November 10, 2022 RANCHO CORDOVA, Calif. , Nov. 7, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing and poi...
ThermoGenesis Holdings, Inc. (THMO) CEO Dr. Chris Xu on Q2 2022 Results - Earnings Call Transcript
13 August 2022
ThermoGenesis Holdings, Inc. (NASDAQ:THMO ) Q2 2022 Results Conference Call August 11, 2022 3:00 PM ET Company Participants Paula Schwartz - Rx Communications Dr. Chris Xu - Chief Executive Officer Je...
ThermoGenesis Holdings to Announce Financial Results for the Second Quarter Ended June 30, 2022 and ...
9 August 2022
Conference Call to be Held on August 11, 2022 RANCHO CORDOVA, Calif. , Aug. 9, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and...
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP II Automated Cell Separation System, an automated cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. It offers PXP Point-of-Care System, an automated sterile system for the automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; PXP-LAVARE System, an automated system designed to wash, re-suspend, and volume reduce cell suspensions; PXP-1000 System, an automated system for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination; and X-Series products, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, X-Mini for small scale cell purification, and X-BACS System under development for large scale cell purification. It also provides CAR-TXpress Platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing, and controls needs. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >